Manipulation of a spider peptide toxin alters its affinity for lipid bilayers and potency and selectivity for voltage-gated sodium channel subtype 1.7

摘要

Huwentoxin-IV (HwTx-IV) is a gating modifier peptide toxin from spiders that has weak affinity for the lipid bilayer. As some gating modifier toxins have affinity for model lipid bilayers, a tripartite relationship among gating modifier toxins, voltage-gated ion channels, and the lipid membrane surrounding the channels has been proposed. We previously designed an HwTx-IV analogue (gHwTx-IV) with reduced negative charge and increased hydrophobic surface profile, which displays increased lipid bilayer affinity and in vitro activity at the voltage-gated sodium channel subtype 1.7 (Na(V)1.7), a channel targeted in pain management. Here, we show that replacements of the positively-charged residues that contribute to the activity of the peptide can improve gHwTx-IV's potency and selectivity for Na(V)1.7. Using HwTx-IV, gHwTx-IV, R26AgHwTx-IV, K27AgHwTx-IV, and R29AgHwTx-IV variants, we examined their potency and selectivity at human Na(V)1.7 and their affinity for the lipid bilayer. R26AgHwTx-IV consistently displayed the most improved potency and selectivity for Na(V)1.7, examined alongside off-target Na(V)s, compared with HwTx-IV and gHwTx-IV. The lipid affinity of each of the three novel analogues was weaker than that of gHwTx-IV, but stronger than that of HwTx-IV, suggesting a possible relationship between in vitro potency at Na(V)1.7 and affinity for lipid bilayers. In a murine Na(V)1.7 engagement model, R26AgHwTx-IV exhibited an efficacy comparable with that of native HwTx-IV. In summary, this study reports the development of an HwTx-IV analogue with improved in vitro selectivity for the pain target Na(V)1.7 and with an in vivo efficacy similar to that of native HwTx-IV.